The Laboratory Role in anti-TNF Biological Therapy Era

  • Valentina Grossi
  • , Francesca Gulli
  • , Maria Infantino
  • , Annunziata Stefanile
  • , Cecilia Napodano
  • , Maurizio Benucci
  • , Krizia Pocino
  • , Francesca Li Gobbi
  • , Arianna Damiani
  • , Antonella Di Pino
  • , Mariangela Manfredi
  • , Mariapaola Marino
  • , Valerio Basile
  • , Gian Ludovico Rapaccini
  • , Umberto Basile

Risultato della ricerca: Contributo in rivistaArticolo

Abstract

Along years, the advent of biological therapy widely modified treatment of rheumatic diseases and other disorders. However, many agents may elicit in anti-drug antibodies (ADAbs) upon consecutive infusions, with a loss of response. For the right strategy of a personalized medicine, the therapeutic monitoring of TNF-α inhibitors and ADAbs represents an important effort in diagnostic–therapeutic pathway, to improve overall patient management and favoring an appropriate clinical approach. A raising number of diagnostic tests have been designed to elucidate the efficacy and/or safety of a specific drug or class of drugs for a targeted patient’s group. Our paper reviewed the current understanding of the immunogenicity of biological drugs employed in the treatment of inflammatory diseases underlying the laboratory role.
Lingua originaleInglese
pagine (da-a)317-332
Numero di pagine16
RivistaImmunological Investigations
Volume49
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • TNF
  • adalimumab
  • anti-TNF drugs
  • certolizumab
  • immunogenicity

Fingerprint

Entra nei temi di ricerca di 'The Laboratory Role in anti-TNF Biological Therapy Era'. Insieme formano una fingerprint unica.

Cita questo